(14) reported that atezolizumab could significantly prolong DFS in patients with resected stage II–IIIA NSCLC after standard adjuvant chemotherapy, with the most significant benefit observed in those with programmed cell death ligand 1 (PD-L1) ≥ 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.